GlassScriptPhysician profile
Christine Cay
NPI 1598478174
$711.47
in general payments reported to CMS, 2019-2025
12 companies · $267 in 2025
The $267 reported for 2025 was more than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $128 · 2024: $317 · 2025: $267.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $711.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $711.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $115.64 | 2023-2024 | Aristada, Vivitrol, Vivitrol |
| Astellas Pharma US INC | $114.06 | 2024-2025 | Veozah |
| Abbvie INC. | $97.75 | 2024-2025 | |
| Indivior INC. | $69.79 | 2023-2024 | Sublocade |
| Ani Pharmaceuticals, INC. | $65.65 | 2025 | Purified Cortrophin Gel |
| Lilly USA, LLC | $57.88 | 2025 | Zepbound, Mounjaro |
| Exact Sciences Corporation | $56.15 | 2023-2025 | Cologuard Collection Kit |
| Hologic Sales and Service, LLC | $45.00 | 2023-2024 | Aptima |
| Agios Pharmaceuticals, INC. | $26.69 | 2025 | Pyrukynd |
| Kiniksa Pharmaceuticals International, Plc | $24.68 | 2024 | Arcalyst |
| Mayne Pharma Commercial LLC | $24.20 | 2025 | |
| Idorsia Pharmaceuticals US INC | $13.98 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Cay listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.